Concurrent Use of Aggrenox and Eliquis

Introduction to Medication Management

• The American Heart Association recommends that anticoagulation therapy for secondary stroke prevention should not be routinely combined with antiplatelet therapy as there is no evidence of additional benefits over using either therapy alone 1, 6

Rationale Against Combination Therapy

• The combination of antiplatelet therapy with anticoagulation significantly increases the risk of major bleeding events, with a notable increase in life-threatening bleeding by 1.3% absolute risk compared to single antiplatelet therapy 2, 3, 4
• The American College of Cardiology suggests that for patients with non-cardioembolic ischemic stroke or TIA, antiplatelet agents rather than oral anticoagulation are recommended, highlighting the importance of tailored treatment approaches 7, 8

Clinical Decision Algorithm

• For patients with atrial fibrillation and history of stroke/TIA, anticoagulation with Eliquis alone is preferred over combination therapy, as it reduces the risk of bleeding complications while maintaining effective stroke prevention 1, 6, 7
• The European Society of Cardiology guidelines indicate that adding antiplatelet therapy to anticoagulation increases bleeding risk without clear additional benefit, emphasizing the need for careful consideration of treatment regimens 2, 3

Special Considerations

• The American Heart Association suggests that if a patient has a stroke while on one antithrombotic agent, guidelines recommend reassessing all vascular risk factors and stroke etiology rather than simply adding another antithrombotic agent, to ensure optimal treatment outcomes 9
• For patients who cannot tolerate aspirin, clopidogrel alone is recommended rather than combination therapy, as it provides effective antiplatelet activity with a lower risk of bleeding complications 7, 8